Literature DB >> 1891001

Glucocorticoids and immunosuppressants do not change the prevalence of necrosis and regeneration in mdx skeletal muscles.

B Weller1, R Massa, G Karpati, S Carpenter.   

Abstract

Therapeutic doses of methylprednisolone, azathioprine, cyclosporin A, and cyclophosphamide administered to mdx mice between 15 and 45 days of age failed to significantly influence the time course and prevalence of necrosis and regeneration or serum creatine kinase activity. This finding contrasts with previously reported findings of beneficial effects of glucocorticoids in Duchenne muscular dystrophy (DMD). This may indicate that, mechanisms upon which beneficial effects of glucocorticoids depend in DMD, do not operate (sufficiently) in mdx mice.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1891001     DOI: 10.1002/mus.880140812

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  10 in total

Review 1.  Understanding dystrophinopathies: an inventory of the structural and functional consequences of the absence of dystrophin in muscles of the mdx mouse.

Authors:  J M Gillis
Journal:  J Muscle Res Cell Motil       Date:  1999-10       Impact factor: 2.698

2.  A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice.

Authors:  Annamaria De Luca; Beatrice Nico; Antonella Liantonio; Maria Paola Didonna; Bodvael Fraysse; Sabata Pierno; Rosa Burdi; Domenica Mangieri; Jean-François Rolland; Claudia Camerino; Alberta Zallone; Paolo Confalonieri; Francesca Andreetta; Elisa Arnoldi; Isabelle Courdier-Fruh; Josef P Magyar; Antonio Frigeri; Michela Pisoni; Maria Svelto; Diana Conte Camerino
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

Review 3.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

4.  Quantitative assessment of the T2 relaxation time of the gluteus muscles in children with Duchenne muscular dystrophy: a comparative study before and after steroid treatment.

Authors:  Hee Kyung Kim; Tal Laor; Paul S Horn; Brenda Wong
Journal:  Korean J Radiol       Date:  2010-04-29       Impact factor: 3.500

5.  Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy.

Authors:  Jin-Hong Shin; Xiufang Pan; Chady H Hakim; Hsiao T Yang; Yongping Yue; Keqing Zhang; Ronald L Terjung; Dongsheng Duan
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

6.  Effects of prednisolone on skeletal muscle contractility in mdx mice.

Authors:  Kristen A Baltgalvis; Jarrod A Call; Jason B Nikas; Dawn A Lowe
Journal:  Muscle Nerve       Date:  2009-09       Impact factor: 3.217

7.  Glucocorticoid efficacy in asthma: is improved tissue remodeling upstream of anti-inflammation.

Authors:  Robert J Freishtat; Kanneboyina Nagaraju; William Jusko; Eric P Hoffman
Journal:  J Investig Med       Date:  2010-01       Impact factor: 2.895

8.  Modulation by prednisolone of calcium handling in skeletal muscle cells.

Authors:  L Metzinger; A C Passaquin; W J Leijendekker; P Poindron; U T Rüegg
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 9.  Therapeutic possibilities in the autosomal recessive limb-girdle muscular dystrophies.

Authors:  Volker Straub; Kate Bushby
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

10.  Glucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouse.

Authors:  Arpana Sali; Alfredo D Guerron; Heather Gordish-Dressman; Christopher F Spurney; Micaela Iantorno; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.